Zobrazeno 1 - 10 of 24 pro vyhledávání: '"Yunbiao Tang"'
1
Akademický článek
Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers
Autor: Pingping Zhang, Yantong Sun, Guobing Shi, Yin Sui, Qiuying Li, Yunbiao Tang, Jingkai Gu
Publikováno v: International Journal of Analytical Chemistry, Vol 2015 (2015)
Our paper aimed to develop rapid, sensitive, and specific LC-MS/MS method for the quantification of niacin (NA) and its metabolite nicotinuric acid (NUA) in human plasma. Following protein precipitation with acetonitrile, the NA, NUA, and internal st
Externí odkaz: https://doaj.org/article/c5b7af6242fc4954aaddc1d6877e309f
Zobrazit plný text záznamu
2
Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions
Autor: Hua Huo, Yunbiao Tang, Wenli Hu, Yin Sui, Qiuying Li
Publikováno v: Drug Design, Development and Therapy
Qiuying Li, Hua Huo, Wenli Hu, Yin Sui, Yunbiao Tang Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of ChinaCorrespondence: Yunbiao Tang; Hua HuoDepartment of Dr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6821404d72e862336ca0d925fb451afe
http://europepmc.org/articles/PMC7699441
Zobrazit plný text záznamu
3
Bioequivalence study of two perindopril tert-butylamine tablet formulations in healthy Chinese subjects under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial
Autor: Zhen Hao, Yunbiao Tang, Qiuying Li, Yan Yu
Publikováno v: Biomedicine & Pharmacotherapy, Vol 135, Iss, Pp 111221-(2021)
Background To evaluate the bioequivalence between test and reference formulations of perindopril tert-butylamine under fasting and fed conditions and to assess their pharmacokinetic (PK) and safety profiles. Method A randomized, open-label, single-do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6695736ec2abc32df364502194d0146d
https://pubmed.ncbi.nlm.nih.gov/33433351
Zobrazit plný text záznamu
4
Bioequivalence study of two formulations of flupirtine maleate capsules in healthy male Chinese volunteers under fasting and fed conditions
Autor: Wenli Hu, Yunbiao Tang, Yanfang Liu, Yujia Sun, Hua Huo, Zhibo Zhao
Publikováno v: Drug Design, Development and Therapy
Yanfang Liu, Hua Huo, Zhibo Zhao, Wenli Hu, Yujia Sun, Yunbiao Tang Technical Center for Clinical Pharmacy, Department of Drug Clinical Trail Management Agency, General Hospital of Shenyang Military Area Command, Shenyang, China Aim: This study devel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89411531764bec9f10a281e1dbba81ed
https://doi.org/10.2147/dddt.s149913
Zobrazit plný text záznamu
5
Pharmacodynamics and pharmacokinetics of ticagrelor vs . clopidogrel in patients with acute coronary syndromes and chronic kidney disease
Autor: Yaling Han, Yunbiao Tang, Chao Li, Jing Qi, Yi Li, Heyang Wang, Jing Li
Publikováno v: British Journal of Clinical Pharmacology. 84:88-96
Background Pivotal clinical trials found that ticagrelor reduced ischaemic complications to a greater extent than clopidogrel, and also that the benefit gradually increased with the reduction in creatinine clearance. However, the underlying mechanism
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::815381853e2e4140da84478d09310855
https://doi.org/10.1111/bcp.13436
Zobrazit plný text záznamu
6
Population pharmacokinetic/pharmacodynamic modelling of nifekalant in healthy Chinese volunteers
Autor: Yanfang Liu, Jiashan Zhang, Yaling Han, Yunbiao Tang, Ying Zan, Hua Huo
Publikováno v: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 151
Nifekalant is a class III antiarrhythmic drug, and its major adverse effect is prolongation of the QT interval. This study analysed data generated from a pharmacokinetic (PK) study to develop a population PK/pharmacodynamics (PD) model for describing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2780057b9c888969c8c478e3ee16f46
https://pubmed.ncbi.nlm.nih.gov/32454129
Zobrazit plný text záznamu
9
Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax
Autor: Yifan, Zhang, Xiaoyan, Chen, Yunbiao, Tang, Youming, Lu, Lixia, Guo, Dafang, Zhong
Publikováno v: Drug Design, Development and Therapy
Purpose The aim of this study was to evaluate the bioequivalence of a generic product 70 mg alendronate sodium tablets with the reference product Fosamax® 70 mg tablet. Materials and methods A single-center, open-label, randomized, three-period, thr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7617212776492849c1da7a867711f918
https://pubmed.ncbi.nlm.nih.gov/28744102
Zobrazit plný text záznamu
10
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease
Autor: Heyang, Wang, Jing, Qi, Yi, Li, Yunbiao, Tang, Chao, Li, Jing, Li, Yaling, Han
Publikováno v: British journal of clinical pharmacology. 84(1)
Pivotal clinical trials found that ticagrelor reduced ischaemic complications to a greater extent than clopidogrel, and also that the benefit gradually increased with the reduction in creatinine clearance. However, the underlying mechanisms remains p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a1762a8cf1a3864662a4615e3c942773
https://pubmed.ncbi.nlm.nih.gov/28921624
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje